ArticleJTCVS open2026
Improved outcomes after modified Stage I palliation for hypoplastic left heart syndrome.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate short- and long-term outcomes after modified Stage I palliation for hypoplastic left heart syndrome. Methods: This retrospective single-center study analyzed 128 patients with hypoplastic left heart syndrome treated between 1993 and 2023. Patients were divided into 2 groups: Era I (n = 36), from 1993 to 2001, included patients who underwent the classic Norwood procedure, and Era II (n = 92), from 2002 to 2023, included patients who underwent modified Stage I palliation. Postoperative outcomes, including the need for postoperative extracorporeal membrane oxygenation, peritoneal dialysis, recoarctation rate, and overall survival, were compared between eras. Results: Median follow-up was 9.7 years, with 100% completeness for survival data, and ranged from 0.9 to 30.9 years. Ninety-day survival improved from 69.4% in Era I to 95.7% in Era II ( Conclusions: On the foundation of important developments in perioperative care across the study period, the introduction of modified Stage I palliation may have contributed to improved survival and reduced postoperative morbidity, and may represent an alternative to centralization of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.